Fig. 3

Fig. 3

MGA Acts Upstream of Bmp2b/swr in the YSL

Embryos injected into the YSL with 1 ng of a 5 bp mismatch control MO, bmpmis2b/swrMO (A–E and K–M), or bmp2b/swrMO (F–J and O–Q).

(A, B, F, and G) Live morphants at the prim-5 stage.

(C and H) gata1 expression at the 8-somite stage.

(D and I) eve1 expression at the prim-5 stage.

(E and J) egr2b expression at the 8-somite stage (12 hpf).

(K and O) pSmad1/5 gradient at 75% epiboly.

(L and P) bmp2b/swr expression at 75% epiboly.

(M) Tail region of prim-5 bmp2bmisMO>YSL morphant, injected at shield stage.

(N) Western blot of 75% epiboly embryo extracts. In acvr1lMO>1-cell morphants, pSmad1: 25% ± 8.6% SD of controls and pSmad5: 21.25% ± 4.7% SD of controls. In bmp2bMO>YSL morphants, pSmad1: 18% ± 2.8% SD of controls and pSmad5: 19% ± 2.8% SD of control levels.

(Q) Tail region of a prim-5 bmp2bMO>YSL morphant, injection at shield stage.

(R and S) Live mgaMOTL3>YSL morphant at the Long-pec stage (<48 hpf), coinjected with 25 pg β-galactosidase mRNA (R) or bmp2b mRNA (S).

(T) The presence (blue) or absence (red) of the ventral tailfin was scored in mgaMOTL3>YSL morphants injected with 25 pg β-galactosidase mRNA or 25 pg bmp2b/swr mRNA and in bmp2bMO>YSL morphants injected with 100 pg β-galactosidase mRNA or 100 pg mouse mga mRNA. Anterior is to the left in (A)–(C), (E)–(H), (J), (M), and (Q)–(S) and up in (D) and (I). Dorsal is to the right in (K), (L), (O) and (P). p d 0.005.

See also Figure S2.